We've already seen more than $100 billion spent on mergers and acquisitions in 2015. That's nearly triple the $37.7 billion we saw in all of 2014.
Archives for November 2015
November 2015 - Page 25 of 26 - Money Morning - Only the News You Can Profit From
UBS: A Stock Market Crash Is Inevitable
A stock market crash in inevitable – we've been saying it for months.
Now a UBS economist, in a note to investors on Friday, predicted the same. "Signs are accumulating that, after six-and-a-half years and price gains of more than 200%, the Bull Market has entered into the 'Late Innings.'"
Dow Jones Industrial Average Slips 21 Points with Earnings in Focus
Find out what's ahead for the stock market today.
Get your update on the Dow Jones Industrial Average, stocks to watch, the biggest stock market news, and today's best profit plays.
Grab Gilead Sciences Stock Before Its Next 66.5% Climb (Nasdaq: GILD)
Sometimes Washington triggers a stock move that can hand us outsized gains. That's exactly what happened with Gilead Sciences Inc. (Nasdaq: GILD).
In March 2014, U.S. Rep. Henry Waxman (D-CA) lashed out at the cost of Gilead's newly approved Hepatitis C (HCV) drug, Sovaldi. Sovaldi runs $84,000, or $1,000 a pill.
But Waxman missed the obvious. Sovaldi (and its newer version Harvoni) cures 90% of HCV patients. That means patients can avoid the need for a liver transplant – an operation that runs $250,000 if an organ donor is found. And that price doesn't include antirejection drugs and antibiotics people must take for the rest of their lives.
Still, Gilead sold off on fears that its high cost would make Medicare look to another HCV drug maker with a less expensive solution. GILD stock lost 13% of its value in a matter of days.
Wall Street was dead wrong…
Medicare actually spent $4.6 billion on Hepatitis C treatments in the first six months of this year. That's almost as much as the agency spent in all of 2014. Gilead accounted for 66% of all covered prescriptions.
And since April 2014, Gilead has gained 66.5% – more than four times that of the S&P 500.
Dow Jones Industrial Average Gains 165 Points on Strong Manufacturing Data
Why did the Dow Jones Industrial Average gain 165 points today?
Here's how the stock market did today, earnings reports, the top stock market news, and stocks to watch based on today's market moves…
HP Company Split: Will Two Stocks Reverse the Tailspin? (HPQ, HPE)
The HP company split of HP Inc. (NYSE: HPQ) and Hewlett Packard Enterprise (NYSE: HPE), official as of yesterday (Sunday), marks a herculean effort to create more shareholder value from two companies than was possible with one.
Both face challenges, but as smaller, more focused companies, they have a better chance of overcoming those challenges than did the unwieldy conglomerate that the old Hewlett Packard had become.
Here's how the HP company split could succeed - and how it could fail...
Fitbit Earnings for Q3 2015 (NYSE: FIT)
Fitbit earnings for Q3 2015 come out after the closing bell today (Monday).
Investors are wondering if Fitbit's financials will suffer from increased competition from Apple Inc. (Nasdaq: AAPL).
Here's how you should play FIT stock after the report...
The Valeant (NYSE: VRX) Stock Price Is Now Under Attack by Charlie Munger
The Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX) stock price is now under attack from iconic investor Charlie Munger.
Munger's attack on Valeant, which began months ago, was renewed this weekend when he spoke out against the stock.
Here's what he has to say about the besieged drug giant.....
Upcoming IPO Calendar: GNST, KURA, XCOM, FGBI
There are four deals kicking off November's upcoming IPO calendar expected to raise a combined $196 million.
Leading the four upcoming IPOs this week is GenSight Biologics SA (Nasdaq: GNST).
Here's everything you need to know about this week's deals...
Election 2016: Jeb Bush’s Memo That No One Got, Plus More Election Coverage
When it comes to the 2016 election, we've got everything you want to know. For example, it looks like GOP presidential hopeful Marco Rubio did not get a key memo sent out by the Bush campaign… all about him, no less.
Plus, Republican presidential hopeful and real estate mogul Donald Trump thinks DNC Chairwoman Debbie Wasserman Schultz is a "crazy, highly neurotic woman" who… does stuff.